Background In a Phase II trial, treatment with the preferential PDE4B inhibitor BI 1015550 prevented a decline in FVC over 12 weeks in patients with idiopathic pulmonary fibrosis (IPF), irrespective of background antifibrotic (AF) use. The effect was seen as early as 2 weeks after treatment initiation.
No takes yet. Share an insight, caveat, or question.
Koschel et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: